ClinicalTrials.gg
WithdrawnNCT02318563Updated Jan 4, 2018

Cannabidiol Oral Solution as an Adjunctive Therapy for Treatment of Participants With Inadequately Controlled Dravet Syndrome

A Phase 3 interventional study of Cannabidiol Oral Solution and Placebo Solution in Dravet Syndrome, sponsored by INSYS Therapeutics Inc. Withdrawn. Open to participants aged 1 Year to 30 Years. Per ClinicalTrials.gov, last updated 2018-01-04.

Sponsored by INSYS Therapeutics Inc · Phase 3, Interventional, and Treatment

Why this study was withdrawn
Sponsor elected not to continue with study.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 3
Study type
Interventional
Enrollment
0
Allocation
Randomized
Ages
1 Year to 30 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 14 studies testing cannabidiol in Epilepsies, Myoclonic — 1 open to participants now, 2 under way, none of them phase 3. Cannabidiol · Epilepsies, Myoclonic.

Enrollment
14th of 14
0 · median 30
Started
2017
with 1 other
Phase 3
8 of 14
none open now
Registered
6th of 14
by date
Lead sponsor
2 of 14
INSYS Therapeutics Inc

Among the 14 studies testing cannabidiol in Epilepsies, Myoclonic, this one is the 14th largest by enrollment, is one of 2 that started in 2017, is one of 8 in phase 3, and was the 6th registered.

Epilepsies, Myoclonic

92 studies on the registry are indexed under Epilepsies, Myoclonic; 21 are open to participants now.

Browse Epilepsies, Myoclonic studies →

Open to participants now

1 of the 14 studies testing cannabidiol in Epilepsies, Myoclonic is open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

About cannabidiol

Cannabidiol: first FDA approval 2018 (EPIDIOLEX), first EMA approval 2019. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 14 Epilepsies, Myoclonic studies recruiting now, 3 (21%) set no upper age limit and 10 (71%) stop at 75 or younger; 11 take children under 18; 3 take healthy volunteers.

This study: 1 Year to 30 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 14 studies testing cannabidiol in Epilepsies, Myoclonic, or all of them as a file.
02

Study summary

This Phase 3 study will enroll participants diagnosed with Dravet Syndrome (DS) who are still experiencing at least one tonic-clonic, clonic, and/or focal seizures with motor components (FSMC) per week, despite ongoing treatment with up to three antiepileptic drugs (AEDs), and meet the other inclusion/exclusion criteria.

Following a 28-day baseline period, participants will begin an 84-day treatment period. Participants will be assigned to receive twice-daily doses of placebo or cannabidiol oral solution at the highest dose determined to be safe in a previous trial.

Following study completion, all participants will be invited to receive Cannabidiol Oral Solution in an open label extension study (under a separate protocol).

03

Conditions studied

  • Dravet Syndrome

Browse trials for

Keywords

  • Treatment-resistant seizures
04

Who can participate

Ages eligible
1 Year to 30 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Meets protocol-specified criteria for qualification and , including clinical diagnosis of DS and onset of seizures according to protocol-specified criteria
  • Is able to speak and understand the language in which the study is being conducted, is able to understand the procedures and study requirements and has voluntarily signed and dated an form approved by the Institutional Review Board before the conduct of any study procedure
  • In the opinion of the Investigator, the subject and/or parent(s)/caregiver(s) are able to keep accurate seizure diaries and the participant is able to take study drug and comply with the protocol, including dosing, medications and diet

Exclusion criteria

Exclusion Criteria:

  • Medical history is outside protocol-specified parameters
  • history of allergic reactions or significant sensitivities to cannabinoids or to any of the other ingredients in the study drug
  • Inadequate supervision by parents or guardians
  • History or current use of dietary supplements, drugs or over-the counter medications outside protocol-specified parameters
  • Signs, symptoms or history of any condition that, per protocol or in the opinion of the investigator, might compromise: 1) the safety or well-being of the participant or study staff; 2) the safety or well-being of the participant's offspring (such as through pregnancy or breast-feeding); 3) the analysis of results
Terms in these criteria, in plain language(4)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Relapsed and refractory

Relapsed: the illness came back after treatment had worked. Refractory: it did not respond to treatment, or stopped responding while still on it.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Phase 3
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Triple (Participant, Care provider, Investigator)
Enrollment
0 participants (actual)

Study arms

  • Experimental
    Cannabidiol Oral Solution

    Participants will receive cannabidiol oral solution at an appropriate dose (no higher than 40 mg/kg/day) determined by data from a previous trial. The total daily dose will be administered in twice daily doses, approximately 12 hours apart.

    Drug: Cannabidiol Oral Solution

  • Placebo comparator
    Placebo Solution

    Participants will receive matching placebo solution administered twice daily, approximately 12 hours apart.

    Drug: Placebo Solution

Interventions

  • An oral solution containing pharmaceutical grade cannabidiol (nonplant-based)

  • DrugPlacebo Solution

    A matching oral solution containing no cannabidiol

06

What researchers measure

Primary outcomes

  1. Percent change in the frequency of tonic-clonic, clonic, and focal seizures with motor components

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

Secondary outcomes

  1. Percent change from baseline in the severity of tonic-clonic, clonic, and focal seizures with motor components

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  2. Percent change from baseline in the duration of tonic-clonic, clonic, and focal seizures with motor components

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  3. Percent change from baseline in the frequency of all seizure activity independent of seizure type

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  4. Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Improvement (CGI-I)

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  5. Change from baseline in parent(s)/caregiver(s) Clinical Global Impressions of Severity (CGI-S)

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  6. Change from baseline in Investigator CGI-I

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

  7. Change from baseline in Investigator CGI-S

    Time frame: Data point for observation period to data point for treatment period Weeks 9 through 12

07

Study locations

No study locations are listed for this record.

08

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Start is estimated for Dec 2017; primary completion for Jun 2018, 5 months later.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 12, 2014
First posted
Dec 17, 2014
StartEst.
Dec 30, 2017
Primary completionEst.
Jun 17, 2018
CompletionEst.
Jun 17, 2018
Last update
Jan 4, 2018
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 4, 2018, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
09

Registry details

Key details

Study ID
NCT02318563
Responsible party
Sponsor
First posted
Dec 17, 2014
Start date
Dec 30, 2017 (estimated)
Primary completion
Jun 17, 2018 (estimated)
Completion
Jun 17, 2018 (estimated)
Last update
Jan 4, 2018

Study contacts

Neha Parikh
study director · INSYS Therapeutics Inc

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is withdrawn, as verified in Jan 2018. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Cannabidiol

Start the discussion